A new window has just opened, illuminating a novel and unsuspected aspect of the pathogenesis of heart failure. As we age, we accumulate somatic mutations in bone marrow stem cells that confer a proliferative advantage, yielding clones in the peripheral blood of mutant leukocytes (Figure).1 Expectedly, those who harbor these clones have a greater liability of developing hematologic cancers, such as acute myeloid leukemia, after accumulating successive mutations that arise in the same clone. Unexpectedly, carriers of these clones of mutant leukocytes have a striking increase in risk of ischemic heart events.2 Because most individuals with these clones will never develop leukemia during their lifespan, this condition has been termed clonal hematopoiesis of indeterminate potential (CHIP). Clonal hematopoiesis of indeterminate potential mutations commonly arise in a surprisingly restricted set of genes. A consensus cut point of 2% of circulating leukocytes that bear such driver mutations defines CHIP.3
Libby P, Jaiswal S, Lin AE, Ebert BL. CHIPping Away at the Pathogenesis of Heart Failure. JAMA Cardiol. 2019;4(1):5–6. doi:10.1001/jamacardio.2018.4039
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.